Protein A Resin Companies

The global protein A resin market is projected to reach USD 2.0 billion by 2030 from USD 1.5 billion in 2025, growing at a CAGR of 6.5% during the forecast period.

The market growth is driven by increased outsourcing of services from pharmaceutical and biopharmaceutical companies to CDMOs and CROs. As leading companies expand multi-plant bio-manufacturing in developed regions, the global monoclonal antibody (mAb) pipeline is growing, evidenced by numerous FDA approvals and the launch of new bispecific antibodies and antibody-drug conjugates. This trend has increased purification needs among end users, supporting an increase in the overall demand for protein A resin, which is expected to grow the market.

Pharmaceutical and biopharmaceutical companies with strong capital expenditure capacity are shifting toward single-use technologies. These methods are characterized by the use of pre-packed columns and membrane resins in upstream and downstream processing, which reduces cleaning and turnaround times. These factors collectively contribute to the rising, sustained demand for protein A resin across established and emerging biomanufacturing hubs.

To know about the assumptions considered for the study download the pdf brochure

The competitive landscape of the protein A resin market features several leading multinational companies that hold significant market share. In addition, some small and medium-sized businesses (SMEs) and regional players also have a notable presence. Key participants in the protein A resin market include Danaher Corporation (US), Merck KGaA (Germany), Repligen Corporation (US), Thermo Fisher Scientific (US), Agilent Technologies (US), GenScript (China), Tosoh Biosciences LLC (Japan), Bio-Rad Laboratories, Inc. (US), Orochem Technologies Inc. (US), Kaneka Corporation (Japan), Ecolab (US), Abcam (UK), and Agarose Bead Technologies (US).

Danaher Corporation (US)

Danaher Corporation is a U.S.-based company that designs, manufactures, and markets medical, industrial, and commercial products and services. Cytiva (formerly GE Healthcare Life Sciences) is globally recognized as the leading manufacturer of protein A chromatography resins, mainly because of its Mab Select product line. Mab Select SuRe and Mab Select PrismA resins are extensively validated across commercial monoclonal antibody (mAb) production platforms. Cytiva operates resin manufacturing facilities with redundant capacity, including its Uppsala (Sweden) site, which was specifically constructed to reduce supply risk. Cytiva’s products are incorporated into numerous approved biologics manufacturing processes worldwide.

The protein A resin products offered by Cytiva exhibit higher dynamic binding capacity (DBC) with enhanced alkaline stability. This results in fewer column cycles and longer resin lifespans in GMP operations, providing practical cost savings. The company's presence across various regions protects it from risks linked to adverse economic trends in a single area. It also gives it access to a large addressable market, boosting its top line.

Merck KGAA (Germany)

Merck KGaA is another leading company in the protein A resin market. It is a major provider of chromatography consumables worldwide. Its main growth strategies include expanding and launching new products to strengthen its global presence. Merck’s strength lies in its long-standing relationships with European biopharmaceutical manufacturers and its diverse portfolio across ion-exchange and mixed-mode chromatography. Eshmuno A resin is known for its extremely low ligand leaching and high alkaline resistance, which especially appeals to customers focused on cleaning validation and regulatory compliance. Through strong R&D efforts, the company is expanding its patent portfolio, helping Merck gain an edge over competitors. Merck consistently launches new chromatography products and is also working on expanding its geographic reach.

Repligen Corporation (US)

Repligen Corporation has developed into a major manufacturer of protein A resin over the past five years. Its co-development agreement with Ecolab has significantly expanded its resin portfolio under the Praesto brand, especially Praesto Jetted A50 and DurA Cycle protein A resins. In terms of technology innovation, Repligen concentrates on protein A ligands that enable lower pH elution and enhanced caustic stability. The company positions its products as more cost-effective alternatives. Mid-size biopharma companies and CDMOs particularly prefer Repligen for its cost-to-performance ratio. Extending its supply agreement with Purolite until 2032 demonstrates Repligen’s long-term strategic vision. Its OPUS pre-packed columns expand its resin application ecosystem, from discovery to clinical-scale use.

Market Ranking

Danaher Corporation (US), through its subsidiary Cytiva, Merck KGaA (Germany), and Repligen Corporation are the leading companies in the global protein A resin market, each holding a strong and strategic position. Danaher, through Cytiva, maintains the leading position mainly due to its widely adopted Mab Select resin family, including Mab Select SuRe and PrismA. These resins are recognized for high dynamic binding capacity, alkaline stability, and broad regulatory acceptance. Repligen, via its Praesto resin line, developed in partnership with Purolite, features jetting technology that improves bead uniformity and process consistency. Repligen’s resin offerings are especially attractive to mid-sized biopharma companies and CDMOs. Merck KGaA, with its Eshmuno® A and ProSep® Ultra resin lines, is known for high alkaline resistance and minimal ligand leaching. Merck’s strong presence in Europe, combined with its integrated bioprocessing solutions—including filtration and single-use systems—sustains its market relevance.

Related Reports:

Protein A Resin Market by Product (Bulk Resin, Lab-scale Columns), Source (Recombinant Protein A), Matrix Type (Agarose-Based Protein A), Application (Monoclonal Antibody Purification, FC-Fusion Protein Purification) & End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com